Valuation: Unicycive Therapeutics, Inc.

Market Cap 141M 123M 113M 105M 200M 13.42B 203M 1.36B 528M 6.58B 529M 518M 22.68B P/E 2026 *
-3.73x
P/E 2027 * 1.03x
Enterprise Value 141M 123M 113M 105M 200M 13.42B 203M 1.36B 528M 6.58B 529M 518M 22.68B EV / Sales 2026 *
33.4x
EV / Sales 2027 * 0.47x
Free-Float
97.64%
Yield 2026 *
79%
Yield 2027 * 44.1%
1 day+3.79%
1 week-32.16%
Current month+18.76%
1 month-22.96%
3 months-19.62%
6 months-3.97%
Current year-3.47%
1 week 3.93
Extreme 3.93
8.43
1 month 3.93
Extreme 3.93
8.56
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
87.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/05Free

Director

126,300 0.5004%
14/05Free

Chief Executive Officer

762,200 3.0201%
14/05Free

Executive/Senior Manager

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
+5.11%-32.16%+20.04%-51.57% 141M
+3.98%+5.55%+76.40%+136.18% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+3.08%+7.72%-10.45%-10.09% 23.75B
+2.01%+4.72%+11.36%+427.23% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+1.81%+3.48%+24.33%+187.92% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +2.91%+3.22%+50.25%+123.12% 23.6B
Weighted average by Cap. +1.97%+6.07%+57.28%+135.40%

Financials

2026 *2027 *
Net sales 4.23M 3.69M 3.39M 3.16M 6M 402M 6.1M 40.84M 15.83M 197M 15.87M 15.53M 680M 300M 262M 241M 225M 426M 28.59B 433M 2.9B 1.12B 14.02B 1.13B 1.1B 48.31B
Net income -40.34M -35.25M -32.37M -30.18M -57.22M -3.84B -58.19M -390M -151M -1.88B -151M -148M -6.49B 186M 163M 149M 139M 264M 17.73B 269M 1.8B 697M 8.69B 699M 684M 29.96B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
03/07/26 USD 5.570 +5.49% 1,851,850
01/07/26 USD 5.280 +12.58% 6,057,842
30/06/26 USD 4.690 -39.09% 20,126,082
29/06/26 USD 7.700 +7.99% 2,593,482
26/06/26 USD 7.130 -13.15% 7,420,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.280USD
Average target price
39.54USD
Spread / Average Target
+648.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock